Filtered By:
Condition: Bleeding
Cancer: Brain Cancers

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 45 results found since Jan 2013.

Platelet Count Predicts Adverse Clinical Outcomes After Ischemic Stroke or TIA: Subgroup Analysis of CNSR II
Conclusion: In ischemic stroke or TIA patients with platelet count within normal range, platelet count may be a qualified predictor for long-term recurrent stroke, mortality, and poor functional outcome. Introduction Platelets exert a critical role in the pathogenesis of atherosclerotic complications of cardio-cerebrovascular disease, contributing to thrombus formation, and embolism (1, 2). Previous literature reported that platelets of various size and density are produced by megakaryocytes of different size and stages of maturation in different clinical conditions, suggesting various platelet patterns in differen...
Source: Frontiers in Neurology - April 11, 2019 Category: Neurology Source Type: research

Nico touts studies using BrainPath to treat hemorrhagic stroke
Nico Corp today released data from 2 recently published studies which utilized its BrainPath Approach to treat hemorrhagic stroke, touting a 95% clot reduction and no mortalities associated with the device. The BrainPath system uses a shunt and specially designed instrumentation to give surgeons access to the subcortical section of the brain. The device won 510(k) clearance from the FDA last June for treating primary and secondary brain tumors, vascular abnormalities, intraventricular tumors or cysts. Data from the studies was published in the journals Neurosurgery and Operative Neurosurgery, the Indianapolis-based c...
Source: Mass Device - June 29, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Neurological Surgical Nico Corp. Source Type: news

Neuroprotective Strategies for Stroke by Natural Products: Advances and Perspectives
Curr Neuropharmacol. 2023 Jul 17. doi: 10.2174/1570159X21666230717144752. Online ahead of print.ABSTRACTCerebral ischemic stroke is a disease with high prevalence and incidence. Its management focuses on rapid reperfusion with intravenous thrombolysis and endovascular thrombectomy. Both therapeutic strategies reduce disability, but the therapy time window is short, and the risk of bleeding is high. Natural products (NPs) have played a key role in drug discovery, especially for cancer and infectious diseases. However, they have made little progress in clinical translation and pose challenges to the treatment of stroke. Rece...
Source: Current Neuropharmacology - July 17, 2023 Category: Drugs & Pharmacology Authors: Aifen Liu Jingyan Hu Tzu-Shao Yeh Chengniu Wang Jilong Tang Xiaohong Huang Bin Chen Liexiang Huangfu Weili Yu Lei Zhang Source Type: research

Fatal Embolic Stroke Due to Non-Atherothrombotic Mobile Thrombi in the Carotid Artery during Gastric Cancer Chemotherapy: An Autopsy Case Report (P01.255)
CONCLUSIONS: Multiple etiologies for ischemic stroke may exist in cancer patients. A mobile thrombus in the carotid artery should be considered as a possible mechanism for arteriogenic stroke in the clinical settings of malignancy with hypercoagulability. Doppler ultrasonography is the most practical tool to identify these conditions.Disclosure: Dr. Yamada has nothing to disclose. Dr. Yoneda has nothing to disclose. Dr. Arakawa has nothing to disclose. Dr. Adachi has nothing to disclose. Dr. Gotoh has nothing to disclose. Dr. Takagi has nothing to disclose.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Yamada, A., Yoneda, J., Arakawa, C., Adachi, T., Gotoh, J., Takagi, M. Tags: P01 Cerebrovascular Disease I Source Type: research

Safety of intravenous thrombolysis for acute ischaemic stroke including concomitant neoplastic disease sufferers – experience from Poland
ConclusionIntravenous thrombolysis performed in Caucasian stroke patients with past or current neoplastic diseases, but not in the course of chemo‐ and radiotherapy, can be a safe and effective method of treatment. In making decision on the thrombolytic treatment, the risk of bleeding complications and the life expectancy should be assessed.
Source: International Journal of Clinical Practice - February 27, 2015 Category: Internal Medicine Authors: P. Sobolewski, W. Brola, W. Szczuchniak, M. Fudala, A. Sobota Tags: Original Paper Source Type: research

Successful Intra-arterial Thrombolysis in a Patient with an Intracranial Meningioma
We report a case of a 78-year-old man who was seen in our emergency department within 2 hours from sudden onset of aphasia, right-sided hemiplegia, hypoesthesia, and homonymous hemianopsia. The National Institutes of Health Stroke Scale (NIHSS) score at admission was 20. Intra-arterial thrombolysis was performed with administration of .3 mg/kg of alteplase combined with mechanical thrombectomy. At discharge, his NIHSS score was 1, and after 90 days, his modified Rankin score was 1. To our knowledge, this is the first report of intra-arterial thrombolysis in a patient with acute ischemic stroke with an intracranial tumor.
Source: Journal of Stroke and Cerebrovascular Diseases - July 8, 2013 Category: Neurology Authors: Robson F. Baiense, Agessandro Abrahão, Irapuá F. Ricarte, Thiago G. Fukuda, Ricardo A. Oliveira, Gisele S. Silva, Maristela Costa, Manoel J. Teixeira Tags: Case Reports Source Type: research

Associations of Anemia With Outcomes in Patients With Spontaneous Intracerebral Hemorrhage: A Meta-Analysis
Conclusions: Anemia on admission was associated with higher mortality and an increased risk of poor outcome in patients with ICH. However, the results were limited by the high heterogeneity of included studies. Prospective, multi-center or population-based, large sample cohort studies are needed in the future. Introduction Intracerebral hemorrhage (ICH) is the second most common cause of stroke and a highly lethal disease (1), which still lacks effective therapeutic interventions (2, 3). Although age, baseline ICH volume and neurological status on admission are well-known predictors of outcome of ICH (4), none of t...
Source: Frontiers in Neurology - April 24, 2019 Category: Neurology Source Type: research

Risk of aspirin-related bleeding is higher in the over-75s
Conclusion This valuable cohort study helps to quantify the extent of bleeding risk in people taking aspirin for secondary prevention of cardiovascular disease. Aspirin is well known to carry bleeding risk – particularly in older adults – but this study suggests the risk may be higher than previously thought. The researchers say that for adults under the age of 75, the annual bleeding risk at around 1% is similar to that suggested by previous trials, as is the ratio of bleeds to the number of cardiovascular events. However, this risk increases for older adults, especially for major bleeds of the stomach and upper diges...
Source: NHS News Feed - June 14, 2017 Category: Consumer Health News Tags: Medication Older people Source Type: news

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Moderate drinking may reduce heart disease risk
Conclusion This study paints a more complicated picture than the "Pint a day keeps the doctor away" story proffered by The Sun. It seems to confirm the findings of other studies, which have shown that non-drinkers tend to have a higher risk of cardiovascular diseases than people who drink moderately. It suggests that some cardiovascular diseases (mainly those directly affecting the heart) seem to have a stronger link to a possible protective effect from alcohol than other vascular diseases, such as mini-strokes and bleeding in the brain. However, this can't be concluded with certainty due to the study design. We ...
Source: NHS News Feed - March 23, 2017 Category: Consumer Health News Tags: Heart/lungs Food/diet Lifestyle/exercise Source Type: news

An Aspirin a Day: Is the Benefit Worth the Risk?
Studies have shown that aspirin, the age old remedy for pain and fever, also thins the blood. Because of this property, it can also help to lower the chances of a heart attack or a stroke caused by a blood clot in the brain. And, although research has found that it only works in certain people (specifically, those with a history of heart attack or stroke) many Americans are inappropriately taking daily, low doses of aspirin as a preventative measure. In fact, researchers have found that about 12 percent of the of nearly 69,000 U.S. adults taking aspirin on a long-term basis should not have received the prescription in the ...
Source: Healthy Living - The Huffington Post - March 13, 2015 Category: Consumer Health News Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

UCLA study shows promise, offers hope for brain hemorrhage patients
A new endoscopic surgical procedure has been shown to be safer and to result in better outcomes than the current standard medical treatment for patients who suffer strokes as a result of brain hemorrhages, UCLA neurosurgeons have announced.   The findings from their potentially groundbreaking, randomized, controlled phase 2 clinical trial, which was conducted at multiple medical centers, were presented last week at the International Stroke Conference in Honolulu.   "These exciting results offer a glimmer of hope for a condition that most doctors have traditionally considered hopeless," said principal investigator...
Source: UCLA Newsroom: Health Sciences - February 11, 2013 Category: Universities & Medical Training Source Type: news